Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripasudil in FED Patients Undergoing FLACS
NCT06048380Phase 3Recruiting
- Sponsor
- Singapore Eye Research Institute
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fuchs endothelial dystrophy (FED) comparing Ripasudil with Placebo (2 arms). Primary endpoint: Average Endothelial Cell Density at 3 months. Started Mar 2025; status: recruiting.
02
Drugs
ripasudil
03
Conditions
Fuchs endothelial dystrophy (FED)
Beyond the preview
Go deeper on NCT06048380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048380.